Is OVERDOSE a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed OVERDOSE.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 2 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported OVERDOSE to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and OVERDOSE. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause OVERDOSE, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes OVERDOSE. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if OVERDOSE ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing OVERDOSE: 2
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where OVERDOSE is a reported side effect: 0.0601%

FDA reports of any drug causing OVERDOSE : 40832
Average percentage for all medicated patients where OVERDOSE is reported as a complication: 0.2559%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with OVERDOSE:

VIOXX (3245 patients)
FOSAMAX (2912 patients)
ZYPREXA (2742 patients)
ACETAMINOPHEN (2520 patients)
SEROQUEL (2508 patients)
ASPIRIN (1620 patients)
OXYCONTIN (1437 patients)
DURAGESIC-100 (1364 patients)
PARACETAMOL (1080 patients)
DIAZEPAM (1017 patients)
NEURONTIN (990 patients)
IBUPROFEN (939 patients)
XANAX (925 patients)
CLOZARIL (920 patients)
CLONAZEPAM (868 patients)
LORAZEPAM (805 patients)
RISPERDAL (775 patients)
LIORESAL (759 patients)
PAXIL (757 patients)
CITALOPRAM HYDROBROMIDE (750 patients)
LYRICA (749 patients)
MORPHINE SULFATE (718 patients)
ZOLOFT (699 patients)
LASIX (685 patients)
LISINOPRIL (685 patients)
PLAVIX (668 patients)
LAMICTAL (658 patients)
MORPHINE (658 patients)
CYMBALTA (651 patients)
AMBIEN (620 patients)
ALCOHOL (617 patients)
FUROSEMIDE (615 patients)
OMEPRAZOLE (614 patients)
SINGULAIR (605 patients)
LEXAPRO (602 patients)
NEXIUM (601 patients)
DIGOXIN (600 patients)
ATENOLOL (595 patients)
METFORMIN HCL (588 patients)
SIMVASTATIN (584 patients)
METHADONE HCL (579 patients)
FORTEO (573 patients)
FENTANYL (568 patients)
ALPRAZOLAM (564 patients)
DEPAKOTE (559 patients)
OXYCODONE HCL (557 patients)
SYNTHROID (552 patients)
KLONOPIN (531 patients)
LEVOTHYROXINE SODIUM (524 patients)
CLOZAPINE (519 patients)
METOCLOPRAMIDE (519 patients)
LIPITOR (518 patients)
WELLBUTRIN (515 patients)
OLANZAPINE (513 patients)
COUMADIN (510 patients)
VALIUM (509 patients)
TRAMADOL HCL (509 patients)
PROZAC (505 patients)
GABAPENTIN (498 patients)
ATIVAN (497 patients)
TRAZODONE HCL (481 patients)
EFFEXOR (480 patients)
ALBUTEROL (468 patients)
VICODIN (467 patients)
RELENZA (464 patients)
FENTANYL-100 (463 patients)
AMLODIPINE (459 patients)
PERCOCET (448 patients)
FLUOXETINE (440 patients)
MIRTAZAPINE (438 patients)
RISPERIDONE (432 patients)
ADVAIR DISKUS 100/50 (416 patients)
TOPAMAX (407 patients)
NORVASC (407 patients)
PAROXETINE HCL (398 patients)
BACLOFEN (397 patients)
PREDNISONE (394 patients)
ABILIFY (391 patients)
ZOCOR (388 patients)
AMITRIPTYLINE HCL (380 patients)
INSULIN (379 patients)
TEGRETOL (378 patients)
ZOMETA (373 patients)
LITHIUM CARBONATE (363 patients)
RISPERDAL CONSTA (354 patients)
TYLENOL (CAPLET) (336 patients)
CARBAMAZEPINE (335 patients)
PREVACID (335 patients)
HALDOL (334 patients)
WARFARIN SODIUM (332 patients)
CELEXA (331 patients)
VALTREX (329 patients)
HYDROCHLOROTHIAZIDE (328 patients)
AVONEX (321 patients)
TEMAZEPAM (320 patients)
LANTUS (313 patients)
[THERAPY UNSPECIFIED] (311 patients)
ZOFRAN (311 patients)
PROTONIX (308 patients)
RAMIPRIL (306 patients)
GEODON (305 patients)
CLONIDINE (301 patients)
PRILOSEC (298 patients)
CELEBREX (296 patients)
FOLIC ACID (292 patients)
FENTANYL TRANSDERMAL SYSTEM (290 patients)
SUBOXONE (289 patients)
NICOTINE (286 patients)
DURAGESIC (284 patients)
METHOTREXATE (279 patients)
ALLOPURINOL (279 patients)
QUETIAPINE (277 patients)
TAMIFLU (276 patients)
LAMOTRIGINE (276 patients)
POTASSIUM CHLORIDE (274 patients)
KEPPRA (273 patients)
SEROXAT (271 patients)
ZOPICLONE (268 patients)
ZOLPIDEM (266 patients)
CONCERTA (260 patients)
SERTRALINE HYDROCHLORIDE (258 patients)
VALPROATE SODIUM (258 patients)
HUMIRA (256 patients)
BENADRYL (256 patients)
NICORETTE (249 patients)
QUETIAPINE FUMARATE (249 patients)
ALENDRONATE SODIUM (244 patients)
METOPROLOL TARTRATE (243 patients)
CHANTIX (239 patients)
ESCITALOPRAM (237 patients)
LANSOPRAZOLE (234 patients)
VENLAFAXINE HCL (232 patients)
NAPROXEN (232 patients)
ZYRTEC (231 patients)
VALPROIC ACID (231 patients)
GLUCOPHAGE (230 patients)
FENTANYL CITRATE (228 patients)
REMERON (228 patients)
METOPROLOL (227 patients)
CITALOPRAM (225 patients)
DIOVAN (224 patients)
ZYPREXA ZYDIS (223 patients)
LORTAB (223 patients)
PREVACID 24 HR (222 patients)
TYLENOL (222 patients)
DILAUDID (221 patients)
PROMETHAZINE (221 patients)
ZANTAC (217 patients)
ETHANOL (216 patients)
COREG (215 patients)
PROPRANOLOL (214 patients)
SPIRIVA (213 patients)
TOPIRAMATE (211 patients)
ULTRAM (210 patients)
EFFEXOR XR (210 patients)
PREMARIN (210 patients)
EXTRA STRENGTH TYLENOL (210 patients)
DIPHENHYDRAMINE HCL (207 patients)
TOPROL-XL (206 patients)
RIVOTRIL (206 patients)
ACTIQ (204 patients)
NITROGLYCERIN (204 patients)
VERAPAMIL (204 patients)
EXCEDRIN (MIGRAINE) (203 patients)
METFORMIN (202 patients)
SEROQUEL XR (201 patients)
PREVISCAN (200 patients)
PREDNISOLONE (199 patients)
DEMEROL (197 patients)
FLEXERIL (196 patients)
COCAINE (195 patients)
SOMA (195 patients)
RANITIDINE (192 patients)
ZOLPIDEM TARTRATE (191 patients)
SPIRONOLACTONE (191 patients)
WELLBUTRIN XL (188 patients)
STRATTERA (188 patients)
MIRALAX (186 patients)
HALCION (186 patients)
AMLODIPINE BESYLATE (186 patients)
VENLAFAXINE (185 patients)
BUPROPION HCL (184 patients)
CRESTOR (183 patients)
ARICEPT (183 patients)
HALOPERIDOL (182 patients)
TYSABRI (182 patients)
VITAMIN D (180 patients)
ADVIL (179 patients)
VOLTAREN (178 patients)
AMOXICILLIN (177 patients)
CORDARONE (176 patients)
LITHIUM (174 patients)
ATARAX (172 patients)
ELAVIL (172 patients)
COZAAR (168 patients)
RITALIN (168 patients)
SERTRALINE (167 patients)
HYDROCODONE BITARTRATE (167 patients)
BYETTA (166 patients)
PREDNISONE TAB (166 patients)
LOVENOX (166 patients)
CALCIUM (165 patients)
DEXAMETHASONE (163 patients)
ALDACTONE (162 patients)
CLARITIN (161 patients)
FOSAMAX PLUS D (161 patients)
PROGRAF (160 patients)
JANUVIA (157 patients)
VENTOLIN (156 patients)
CARVEDILOL (156 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about OVERDOSE and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.